- Cellares has entered a collaboration with Stanford Medicine groups to automate manufacturing and release testing for gene-edited hematopoietic stem cell therapies.
- The work expands Cellares’ automation platforms beyond T cell therapies into a new cell modality and aims to support scalable clinical development.
Cellares has announced a collaboration with the Stanford Center for Definitive and Curative Medicine and the Stanford Innovative Medicines Accelerator to automate manufacturing and release testing for gene-edited hematopoietic stem cell therapies. The effort expands the use of Cellares’ automation platforms beyond T cell therapies into hematopoietic stem cells.
Under the collaboration, Cellares will establish a standardized manufacturing process on its Cell Shuttle™ platform and develop platform release assays on Cell Q™. The approach is designed to be applied across multiple indications and is already being used with the HARBOR KNOCK gene-editing strategy.
Gene-edited hematopoietic stem cells are being developed as potentially one-time treatments intended to rebuild the blood and immune system for patients with HIV and rare inherited diseases. According to the collaborators, these programmes require scalable and consistent manufacturing approaches to support broader patient access as development progresses.
The work is supported by the Stanford Innovative Medicines Accelerator and the Stanford Medicine Center for Definitive and Curative Medicine. The collaboration aims to reduce hands-on variability and create a scalable manufacturing foundation to help translate academic research into clinical-stage programmes.
“Gene-edited hematopoietic stem cells have the potential to address the root cause of disease for patients who today have limited or no treatment options. The collaboration is focused on building a manufacturing and analytical foundation that can be applied across multiple rare disease programmes.”
Fabian Gerlinghaus, Co-founder and CEO of Cellares
